Division of Hematology, Medicinal Chemistry Section, University of Messina, Italy.
Acta Haematol. 2012;127(1):1-6. doi: 10.1159/000330948. Epub 2011 Oct 4.
The aim of the present study was to determine serum levels of neutrophil gelatinase-associated lipocalin (NGAL) and leptin in patients with chronic myeloid leukemia (CML) at diagnosis and after imatinib therapy when patients achieved a complete molecular remission. The study was conducted on 22 patients with CML in the chronic phase and 10 healthy subjects. The median serum NGAL levels in CML patients at diagnosis were significantly higher compared to age-matched controls. After imatinib therapy, all patients achieved complete molecular remission and NGAL levels decreased and were found significantly lower with respect to the baseline. No significant correlations were found between NGAL levels and other disease parameters. Before imatinib therapy, the median blood leptin levels were not significantly different from those of controls. After therapy with imatinib, all patients in molecular remission presented an increase in leptin levels. Future research is eagerly awaited as it may demonstrate the real role of NGAL and leptin in the onset and progression of CML.
本研究旨在测定慢性髓系白血病（CML）患者在诊断时和伊马替尼治疗后达到完全分子缓解时的中性粒细胞明胶酶相关脂质运载蛋白（NGAL）和瘦素的血清水平。该研究共纳入 22 例慢性期 CML 患者和 10 名健康对照者。与年龄匹配的对照组相比，CML 患者在诊断时的中位血清 NGAL 水平明显升高。在伊马替尼治疗后，所有患者均达到完全分子缓解，NGAL 水平降低，与基线相比显著降低。未发现 NGAL 水平与其他疾病参数之间存在显著相关性。在伊马替尼治疗前，中位血瘦素水平与对照组无显著差异。在接受伊马替尼治疗后，所有分子缓解的患者瘦素水平均升高。未来的研究备受期待，因为它可能证明 NGAL 和瘦素在 CML 的发生和发展中的真正作用。
